Loading Icon

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
More from Wikipedia

Metrics Summary

Total Publications
Lifetime
581
Prior Five Years
169
Total Citations
Lifetime
18,835
Prior Five Years
1,290
Total Scholars
Lifetime
199
Prior Five Years
124

Non-academic Institutional Ranking

Global Overall (All Fields)

Worldwide

Lifetime
3442
Prior Five Years
N/A
National Overall (All Fields)

Lifetime
N/A
Prior Five Years
N/A
Institutional Rankings

Fields, Disciplines and Specialties

Lifetime
View
Prior Five Years
View
Global Field
Lifetime		 Global Discipline
Lifetime		 Global Specialty
Lifetime
N/A
N/A
#1
RNAI
#1
Gene silencing
#2
Intercellular adhesion molecule
#4
Oligonucleotide
#7
Sonic hedgehog
#12
RNA interference
#19
Nucleoside
#21
Cell adhesion molecule
#25
Chemical biology
#47
Nucleic acid
Show More
Show More

Publications and Citation History

Publications based on Fields

Scholars based on Fields

Publications based on Top 20 Disciplines

Scholars based on Top 20 Disciplines

Highly Ranked Scholars™

Overall (All Fields)
Lifetime
Field
Lifetime
Discipline
Lifetime
Specialty
Lifetime

Top Scholars by Institution

Highly Cited Publications

Lifetime